Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, today announced it has raised $70 million in Series C funding. The Series C round was co-led by New Enterprise Associates (NEA) and Revolution Growth. This latest round brings the two-year-old company’s total funding to $130M.
Cancer isn’t only about where it grows. It’s about how it grows. Genetic alterations drive cancer growth. Some treatments address these specific alterations. For patients, knowing which
Founded in 2015, Tempus provides genomic and transcriptomic sequencing servcies and analyzes somatic and germline molecular data along with therapeutic data. Through their interactive analytical and machine learning platform, Tempus enable physicians to deliver personalized cancer care for patients.
Tempus has landed personalized cancer care partnerships with leading providers such as Cleveland Clinic, Duke University School of Medicine, Mayo Clinic, Northwestern’s Lurie Cancer Center, Penn’s Abramson Cancer Center, University of Chicago Medicine, University of Michigan and community hospitals across the country.
“In oncology, and across healthcare more broadly, datasets have historically been small and disorganized,” said Eric Lefkofsky, Founder and CEO at Tempus in a statement. “Thankfully, technology has opened the door to new possibilities and for the first time in history, it is possible to amass massive amounts of molecular and clinical data and put it to work for the benefit of patients.”
